Glutathione
Investigación publicada y base de evidencia
Glutathione (GSH) is an endogenous tripeptide (glutamate-cysteine-glycine) that functions as the principal intracellular thiol antioxidant and redox buffer. Human research falls into four broad strands: pharmacokinetic work comparing standard oral, liposomal/micellar and intravenous delivery; dermatological trials of oral, topical and intravenous glutathione for skin pigmentation; clinical trials of intravenous, inhaled or oral glutathione in conditions such as contrast-induced kidney injury, chemotherapy neuropathy and cystic fibrosis, with mixed and often null results; and precursor-based repletion strategies, most prominently glycine plus N-acetylcysteine (GlyNAC), studied in ageing, HIV and metabolic disease. Trial sizes are generally small, outcome measures are heterogeneous, and results in neurodegeneration have been largely negative for direct glutathione administration while precursor approaches have shown more consistent biochemical effects.
- El glutatión es un tripéptido formado por glutamato, cisteína y glicina.
- Ensayos humanos probaron formas orales, tópicas, inhaladas e IV para la piel y otras afecciones.
- La mayoría de los ensayos fueron pequeños; los grandes ensayos IV en lesión renal y neuropatía no hallaron beneficio.
43 estudios · 12 desde 2023 · más reciente 2026
- Estudios citados
- 43
- Publicados en 2023+
- 12
- Artículo más reciente
- 2026
- Última revisión
- oct 2026
Temas recurrentes en la literatura
- Oral bioavailability of glutathione is contested; formulation (liposomal, micellar, orally dissolving film) substantially changes systemic exposure
- Repeated oral dosing raises whole-blood, erythrocyte and lymphocyte glutathione pools in healthy adults, with return to baseline after washout
- Skin-lightening trials report reductions in melanin index with oral and topical glutathione, but short durations and high risk of bias
- Intravenous glutathione for cosmetic or longevity indications lacks controlled efficacy data and carries documented safety concerns
- Direct glutathione administration in Parkinson's disease has not outperformed placebo; precursor supply via N-acetylcysteine shows more signal
- GlyNAC (glycine + N-acetylcysteine) corrects glutathione deficiency and oxidative stress markers in older adults and in people with HIV
- Oral glutathione lowered aminotransferases in an uncontrolled NAFLD pilot; no randomised confirmation
Identificadores del compuesto
- CAS
- 70-18-8
- PubChem
- 124886
Qué es Glutathione, químicamente.
- Fórmula molecular
- C10H17N3O6S
- Peso molecular
- 307.33 g/mol
- Número CAS
- 70-18-8
- PubChem CID
- 124886
L-Glutathione
Estas cifras provienen del registro PubChem para este compuesto y describen la base libre. El péptido liofilizado normalmente se suministra como sal de acetato o trifluoroacetato y contiene agua residual, por lo que la masa de polvo en un vial no es la misma cantidad que sugeriría el peso molecular anterior. La pureza cromatográfica en un certificado de análisis tampoco resuelve esa diferencia — cómo leer un certificado de análisis explica por qué.
43 estudios publicados.
Ordenados por solidez del diseño del estudio, luego por antigüedad. Cada entrada enlaza a su registro fuente para que el hallazgo pueda verificarse contra el artículo en lugar de tomarse bajo nuestra palabra.
- 01Guía clínica2026
Safety of S-acetyl glutathione as an novel food pursuant to Regulation (EU) 2015/2283.
EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) · EFSA J · EFSA NDA Panel scientific opinion on S-acetyl glutathione as a novel food under EU Regulation 2015/2283
The Panel concluded the novel food was safe for adults at the proposed use level as a food supplement, excluding pregnant and lactating women, and set lower safe intake levels for adolescents derived from benchmark-dose modelling of liver-to-body-weight ratio; perchlorate exposure stayed below the tolerable daily intake.
Hallazgo de seguridad reportado. EFSA identified increased liver-to-body-weight ratio in animal studies as the critical effect and did not assess the ingredient as safe for pregnant or lactating women or children under 10.
- 02Revisión sistemática2026
The role of N-acetylcysteine and glutathione in the management of Parkinson's disease: a systematic review of oxidative biomarkers and clinical outcomes
Mohammed I, Nankya Y, Hong UT, et al. · Amino Acids · systematic review of 9 studies (2009-2019) totalling 196 participants with Parkinson's disease, comparing NAC or glutathione against placebo or healthy controls
N-acetylcysteine improved motor and non-motor symptoms and increased GSH/GSSG ratios, cerebrospinal fluid GSH and dopamine transporter binding, whereas intranasal glutathione produced only modest increases in brain glutathione without significant symptomatic or oxidative-stress benefit. The reviewers judged evidence for glutathione itself inconclusive.
- 03Revisión sistemática2025
Glutathione as a skin-lightening agent and in melasma: a systematic review
Sarkar R, Yadav V, Yadav T, et al. · International Journal of Dermatology · systematic review of 10 years of PubMed, Embase and Cochrane records on topical, oral and intravenous glutathione for skin lightening and melasma
Five randomised controlled trials and one open-arm study of oral glutathione at 250-500 mg/day reported significant reductions in melanin index versus placebo, and combined topical plus oral glutathione outperformed monotherapy. Only one placebo-controlled study of intravenous glutathione was identified, and roughly half the included studies carried a high risk of bias.
- 04Clínico humano2026
A Targeted Metabolomic Assessment of Oral Glutathione Bioavailability and Safety in Humans: A Randomized Crossover Clinical Trial
Solnier J, Du M, Zhang Y, et al. · Antioxidants (Basel) · randomized double-blind crossover, 14 healthy adults, single oral doses of micellar vs standard vs liposomal glutathione, plus 30-day single-arm safety phase at 600 mg/day
Micellar glutathione (300 mg) produced roughly 2.5-fold higher baseline-adjusted whole-blood GSH exposure and peak response than standard glutathione (500 mg), and a higher GSH/GSSG ratio. Thirty days of daily dosing produced no significant change in ALT, AST, ALP or creatinine.
- 05Clínico humano2026
Liposomal glutathione outperforms plain glutathione in uptake, cell regeneration and systemic availability: evidence from cellular and human models
Prasad KN, Chandrashekar C, Karthik Y, et al. · British Journal of Nutrition · HEK293T cell assays plus parallel-arm open-label human pharmacokinetic study, 12 healthy adults (6 per arm), single 1 g oral dose
The liposomal formulation reached a maximum plasma concentration approximately six times higher than plain glutathione, showed bimodal absorption and retained plasma levels above 500 ng/mL at 24 hours. Cellular uptake was about 1.9-fold higher in vitro.
- 06Clínico humano2026
Formulation-dependent differences in systemic glutathione availability: Comparative pharmacokinetics of orally dissolving film and tablet formulations in healthy adults
Jung ES, Jang HY, Jung SJ, et al. · European Journal of Pharmaceutics and Biopharmaceutics · randomized open-label crossover single-dose 300 mg pharmacokinetics, plus 4-week supplementation at 100 mg/day, healthy adults (CRIS KCT0011710)
Plasma glutathione concentrations were higher with the orally dissolving film than with tablets, reaching significance at 4 and 6 hours, with a longer time to maximum concentration. The authors described only a trend toward greater overall systemic exposure.
- 07Clínico humano2025
Therapeutic effects of reduced glutathione on liver function, fibrosis, and HBV DNA clearance in chronic hepatitis B patients.
Wei Q, Zhao J · BMC Gastroenterol · randomised controlled trial, n=90 patients with chronic hepatitis B, reduced glutathione plus entecavir versus entecavir alone for 3 months, HBV-DNA followed to 48 weeks
ALT, bilirubin and albumin improved more, fibrosis markers fell more and HBV-DNA negative conversion at 48 weeks was higher with combination therapy (68.89% vs 42.22%, P < 0.05). Adverse reactions occurred in 8.89% versus 20.00% (P > 0.05). The abstract does not state the glutathione route or whether the trial was blinded.
- 08Clínico humano2023
Supplementing Glycine and N-Acetylcysteine (GlyNAC) in Older Adults Improves Glutathione Deficiency, Oxidative Stress, Mitochondrial Dysfunction, Inflammation, Physical Function, and Aging Hallmarks: A Randomized Clinical Trial
Kumar P, Liu C, Suliburk J, et al. · The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences · placebo-controlled randomized trial, 24 older adults randomised to GlyNAC or isonitrogenous alanine placebo for 16 weeks, plus 12 young adults given GlyNAC for 2 weeks
Older adults had baseline glutathione deficiency, elevated oxidative stress, mitochondrial dysfunction, inflammation, insulin resistance and impaired physical function relative to young adults; GlyNAC supplementation improved these measures over 16 weeks. The trial was small and single-centre.
- 09Clínico humano2021
Glutathione Infusion Before and 3 Days After Primary Angioplasty Blunts Ongoing NOX2-Mediated Inflammatory Response.
Tanzilli G, et al. · J Am Heart Assoc · randomised placebo-controlled trial (GSH2014), one hundred patients with ST-elevation myocardial infarction undergoing primary angioplasty, intravenous glutathione before angioplasty and for 3 days afterwards, 6-month follow-up
After reperfusion, neutrophil-to-lymphocyte ratio, hsCRP, NOX2 activation, TNF-alpha and troponin T release were lower with glutathione than with placebo (P<0.0001 to P<0.001), and the blunted inflammatory response correlated with left ventricular size and function at follow-up (r=0.78).
- 10Clínico humano2021
Combination of topical and oral glutathione as a skin-whitening agent: a double-blind randomized controlled clinical trial.
Wahab S, et al. · Int J Dermatol · double-blind randomised controlled trial, n=46 participants given oral glutathione or oral placebo, each also applying topical glutathione to one side of the face and topical placebo to the other, 8 weeks
Combined oral and topical glutathione gave a significantly lower melanin index and higher L* lightness than placebo (P < 0.05), and the authors concluded that both routes lightened skin, with combination possibly better than either alone.
- 11Clínico humano2021
The effects of 3 weeks of oral glutathione supplementation on whole body insulin sensitivity in obese males with and without type 2 diabetes: a randomized trial.
Søndergård SD, et al. · Appl Physiol Nutr Metab · randomised double-blind placebo-controlled trial, twenty obese men (10 with type 2 diabetes, 10 without), 3 weeks of oral glutathione
Whole-body insulin sensitivity measured by hyperinsulinaemic-euglycaemic clamp increased significantly in the glutathione group. Skeletal muscle glutathione rose numerically (about 19%), while muscle mitochondrial H2O2 emission and urinary oxidation markers did not change.
- 12Clínico humano2020
Oral Glutathione and Growth in Cystic Fibrosis: A Multicenter, Randomized, Placebo-controlled, Double-blind Trial.
Bozic M, et al. · J Pediatr Gastroenterol Nutr · multicenter randomized double-blind placebo-controlled phase II trial (GROW), n=58 children aged 2-10 with cystic fibrosis, 24 weeks
Oral glutathione did not change weight-for-age z-score, weight, BMI, or serum and fecal inflammatory markers versus placebo; it was safe and well tolerated.
- 13Clínico humano2020
Impact of Glutathione and Vitamin B-6 in Cirrhosis Patients: A Randomized Controlled Trial and Follow-Up Study.
Lai CY, et al. · Nutrients · double-blind randomised placebo-controlled four-arm trial, n=61 patients with liver cirrhosis, 12 weeks of glutathione, vitamin B-6, both, or placebo, then a median 984-day follow-up
Neither glutathione nor vitamin B-6 supplementation changed indicators of oxidative stress or antioxidant capacity. Higher baseline glutathione status was associated with lower Child-Turcotte-Pugh scores.
- 14Clínico humano2018
Oral supplementation with liposomal glutathione elevates body stores of glutathione and markers of immune function
Sinha R, Sinha I, Calcagnotto A, et al. · European Journal of Clinical Nutrition · 1-month open pilot study, 12 healthy adults, oral liposomal glutathione 500 or 1000 mg/day
Glutathione increased by up to 40% in whole blood and 100% in peripheral blood mononuclear cells by 2 weeks, alongside a 35% fall in plasma 8-isoprostane. No differences were detected between dose groups, and the study was uncontrolled with limited statistical power.
- 15Clínico humano2017
Phase IIb Study of Intranasal Glutathione in Parkinson's Disease
Mischley LK, Lau RC, Shankland EG, et al. · Journal of Parkinson's Disease · double-blind placebo-controlled trial, 45 participants with Hoehn & Yahr stage 1-3 Parkinson's disease, intranasal glutathione 100 or 200 mg three times daily for 3 months
All cohorts including placebo improved, and neither glutathione dose was superior to placebo on total or motor UPDRS scores. One participant in the high-dose group developed cardiomyopathy.
- 16Clínico humano2017
Efficacy of glutathione for the treatment of nonalcoholic fatty liver disease: an open-label, single-arm, multicenter, pilot study
Honda Y, Kessoku T, Sumida Y, et al. · BMC Gastroenterology · open-label single-arm multicentre pilot, 34 enrolled (29 completed) NAFLD patients, oral glutathione 300 mg/day for 4 months after a 3-month lifestyle run-in
Alanine aminotransferase decreased significantly after 4 months of oral glutathione, along with triglycerides, non-esterified fatty acids and ferritin. There was no control arm, so the contribution of the preceding lifestyle intervention could not be separated.
- 17Clínico humano2017
Glutathione and its antiaging and antimelanogenic effects.
Weschawalit S, et al. · Clin Cosmet Investig Dermatol · randomised double-blind placebo-controlled three-arm trial in healthy women, 12 weeks of oral reduced glutathione, oral oxidised glutathione or placebo
Melanin index and ultraviolet spots tended to be lower with both glutathione forms than with placebo, and reduced glutathione significantly reduced wrinkles at some sites compared with placebo. There were no serious adverse effects.
- 18Clínico humano2015
Randomized controlled trial of oral glutathione supplementation on body stores of glutathione
Richie JP Jr, Nichenametla S, Neidig W, et al. · European Journal of Nutrition · 6-month randomized double-blind placebo-controlled trial, 54 non-smoking adults, oral glutathione 250 or 1000 mg/day
At 6 months, glutathione rose about 30-35% in erythrocytes, plasma and lymphocytes and 260% in buccal cells in the high-dose group, with dose- and time-dependent effects that returned to baseline after a 1-month washout. Natural killer cell cytotoxicity increased more than twofold versus placebo at 3 months.
- 19Clínico humano2015
Reduced Glutathione for Prevention of Renal Outcomes in Patients Undergoing Selective Coronary Angiography or Intervention.
Wang C, et al. · J Interv Cardiol · randomised placebo-controlled trial, n=825 patients undergoing selective coronary angiography and/or intervention, single intravenous dose of reduced glutathione
Contrast-induced acute kidney injury occurred in 5.07% with glutathione and 4.97% with placebo (relative risk 1.04, P = 0.886), and changes in malondialdehyde and total antioxidant capacity did not differ significantly.
- 20Clínico humano2015
Preventive effect of reduced glutathione on contrast-induced nephropathy in elderly patients undergoing coronary angiography or intervention: a randomized, controlled trial.
Jin B, et al. · Braz J Med Biol Res · randomised controlled trial, n=505 patients aged 75 or older undergoing non-emergency coronary angiography or intervention, hydration plus reduced glutathione versus hydration alone
Contrast-induced nephropathy occurred in 6.49% with glutathione and 7.41% with hydration alone (P=0.68), with no difference in the PCI subgroup.
- 21Clínico humano2015
Randomized, single blind, controlled trial of inhaled glutathione vs placebo in patients with cystic fibrosis.
Calabrese C, et al. · J Cyst Fibros · single-blind randomised placebo-controlled trial in 54 adults and 51 children with cystic fibrosis, 12 months of inhaled glutathione
The predetermined primary outcome of a 15% FEV1 improvement was not met. FEV1 rose from baseline at 3, 6 and 9 months only in patients with moderate lung disease, 6-minute walk improved in children, and glutathione was well tolerated.
- 22Clínico humano2015
Oral reduced L-glutathione improves growth in pediatric cystic fibrosis patients.
Visca A, et al. · J Pediatr Gastroenterol Nutr · randomised double-blind placebo-controlled trial, n=44 children with cystic fibrosis aged 18 months to 10 years, 6 months of oral reduced glutathione
The glutathione group gained 0.67 SD in weight-for-age z score versus 0.1 SD on placebo (P < 0.0001), with improvements in BMI, height and fecal calprotectin, and no adverse effects were reported.
- 23Clínico humano2015
A randomized, double-blind phase I/IIa study of intranasal glutathione in Parkinson's disease.
Mischley LK, et al. · Mov Disord · randomised double-blind placebo-controlled phase I/IIa trial, n=30 people with Parkinson's disease, 3 months of intranasal glutathione at two doses or saline
There were no substantial differences between groups in adverse events across all safety measures, and all groups met tolerability criteria. The trial was designed to assess safety and tolerability, not efficacy.
- 24Clínico humano2014
North Central Cancer Treatment Group/Alliance trial N08CA-the use of glutathione for prevention of paclitaxel/carboplatin-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled study.
Leal AD, et al. · Cancer · phase 3 randomised double-blind placebo-controlled trial (NCCTG/Alliance N08CA), n=185 patients receiving paclitaxel and carboplatin, glutathione infused before each chemotherapy
Glutathione did not reduce chemotherapy-induced peripheral neuropathy on the EORTC CIPN20 sensory scale (P = .21) or CTCAE grading; time to grade ≥2 neuropathy (P = .039) and paclitaxel acute pain syndrome with weekly paclitaxel (P = .002) favoured placebo, and time to progression and toxicities did not differ.
- 25Clínico humano2013
Inhalation treatment with glutathione in patients with cystic fibrosis. A randomized clinical trial.
Griese M, et al. · Am J Respir Crit Care Med · multicentre randomised double-blind placebo-controlled trial in patients with cystic fibrosis (n = 73 glutathione, n = 80 placebo) aged 8 and older with FEV1 40-90% predicted, 6 months of nebulised glutathione
Inhaled glutathione did not improve the primary FEV1 endpoints (P = 0.180 and P = 0.205), pulmonary exacerbations or quality of life; an exploratory FEV1 gain over placebo (2.2% predicted) was significant only at 3 months. Sputum glutathione rose, but markers of oxidation, inflammation and proteolysis did not change, and adverse events were similar to placebo.
- 26Clínico humano2012
Glutathione as an oral whitening agent: a randomized, double-blind, placebo-controlled study
Arjinpathana N, Asawanonda P · Journal of Dermatological Treatment · randomized double-blind placebo-controlled trial, 60 healthy adults in Bangkok, oral glutathione 500 mg/day for 4 weeks
Melanin indices decreased at all six measured sites in the glutathione arm, reaching statistical significance versus placebo at two sites (right face and sun-exposed left forearm). Both arms were well tolerated, and the authors noted that long-term safety was not established.
- 27Clínico humano2011
Effects of oral glutathione supplementation on systemic oxidative stress biomarkers in human volunteers.
Allen J, et al. · J Altern Complement Med · randomized double-blind placebo-controlled trial, n=40 healthy adults, 4 weeks
Oral glutathione produced no significant changes versus placebo in urinary F2-isoprostanes, urinary 8-OHdG, or erythrocyte reduced/oxidized glutathione and their ratio.
- 28Clínico humano2009
Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson's disease.
Hauser RA, et al. · Mov Disord · randomized double-blind placebo-controlled pilot trial, n=21 Parkinson's disease patients, 4 weeks IV treatment + 8 weeks follow-up
IV glutathione was well tolerated with adverse events similar to placebo, but produced no significant differences in UPDRS score changes during treatment or follow-up.
- 29Clínico humano2002
Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial.
Cascinu S, et al. · J Clin Oncol · randomized double-blind placebo-controlled trial, n=52 patients with advanced colorectal cancer on oxaliplatin-based chemotherapy
Grade 2-4 neuropathy after 8 cycles occurred in 2 patients on glutathione versus 11 on placebo (P=.003); sural nerve conduction declined only in the placebo arm, and tumor response rates were similar (26.9% vs 23.1%).
- 30Clínico humano2002
Effect of glutathione infusion on leg arterial circulation, cutaneous microcirculation, and pain-free walking distance in patients with peripheral obstructive arterial disease: a randomized, double-blind, placebo-controlled trial.
Arosio E, et al. · Mayo Clin Proc · randomised double-blind placebo-controlled trial, forty patients with Fontaine stage II peripheral artery disease, 5 days of intravenous glutathione
Pain-free walking distance increased with glutathione (196 vs 143 m; P<.04), with greater post-exercise macrocirculatory flow and post-ischaemic microcirculatory hyperaemia; resting measures did not change. Measurements were repeated 12 hours after the last infusion.
- 31Clínico humano2001
Management of chronic otitis media with effusion: the role of glutathione.
Testa B, et al. · Laryngoscope · randomised placebo-controlled trial, n=60 children with chronic otitis media with effusion, 2 weeks of glutathione by nasal aerosol versus saline
Three months after treatment, improvement was seen in 66.6% of the glutathione group and 8% of controls (P <.01).
- 32Clínico humano1997
Glutathione reduces the toxicity and improves quality of life of women diagnosed with ovarian cancer treated with cisplatin: results of a double-blind, randomised trial.
Smyth JF, et al. · Ann Oncol · double-blind randomised trial, n=151 women with ovarian cancer receiving cisplatin
More patients completed six cisplatin cycles with glutathione than without (58% vs 39%), with less decline in creatinine clearance and better quality-of-life scores (depression, emesis, peripheral neurotoxicity, concentration); tumor response trended higher but not significantly.
- 33Clínico humano1997
Nebulized glutathione induces bronchoconstriction in patients with mild asthma.
Marrades RM, et al. · Am J Respir Crit Care Med · randomised double-blind placebo-controlled crossover study, n=8 patients with mild asthma, single nebulised dose of glutathione or saline
Nebulised glutathione caused major airway narrowing (FEV1 -19%, respiratory resistance +61%) compared with mild changes on placebo, with cough in four and breathlessness in three patients. Salbutamol pretreatment blocked the effect, which the authors attributed to sulfite formation.
Hallazgo de seguridad reportado. Nebulised glutathione induced significant bronchoconstriction, cough and breathlessness in patients with mild asthma.
- 34Clínico humano1996
Reduced intravenous glutathione in the treatment of early Parkinson's disease
Sechi G, Deledda MG, Bua G, et al. · Progress in Neuro-Psychopharmacology & Biological Psychiatry · open-label uncontrolled study, 9 patients with early untreated Parkinson's disease, intravenous glutathione 600 mg twice daily for 30 days
All patients improved on two disability rating scales, with a reported 42% decline in disability that persisted 2-4 months after discontinuation. The study had no placebo control, no blinding and a sample of nine.
- 35Clínico humano1995
Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: a randomized double-blind placebo-controlled trial.
Cascinu S, et al. · J Clin Oncol · randomised double-blind placebo-controlled trial, fifty patients with advanced gastric cancer on cisplatin-based chemotherapy, intravenous glutathione before cisplatin followed by intramuscular glutathione
After 15 weeks, neurotoxicity occurred in 4 of 24 assessable patients given glutathione versus 16 of 18 on placebo (P = .0001), sensory nerve conduction declined only in the placebo arm, and response rate was 76% versus 52%. Glutathione was also associated with fewer transfusions and treatment delays.
- 36Clínico humano1993
Placebo-controlled, double-blind, cross-over trial of glutathione therapy in male infertility.
Lenzi A, et al. · Hum Reprod · randomised double-blind placebo-controlled crossover trial, n=20 infertile men with dyspermia linked to varicocele or genital tract inflammation, 2 months of intramuscular glutathione then crossover
Compared with placebo, glutathione significantly improved sperm motility, particularly forward motility and computer-analysed kinetic parameters, and sperm morphology.
- 37Clínico humano1992
The systemic availability of oral glutathione.
Witschi A, et al. · Eur J Clin Pharmacol · single-dose pharmacokinetic study, n=7 healthy volunteers, 270-minute sampling
After a single oral dose of glutathione, plasma glutathione, cysteine and glutamate did not increase significantly; the authors concluded that systemic availability of oral glutathione was negligible, attributing this to hydrolysis by intestinal and hepatic gamma-glutamyltransferase.
- 38Revisión2026
Intravenous longevity therapy: a critical review of evidence, mechanisms, and clinical utility
Godic A, Townsend J · Acta Dermatovenerologica Alpina, Pannonica et Adriatica · critical review of intravenous high-dose vitamin, amino acid, glutathione and NAD+ infusion protocols marketed as longevity therapy
Available data came mainly from preclinical models and small clinical series in disease-specific or aesthetic contexts, with scarce and underpowered placebo-controlled trials and substantial heterogeneity of infusion protocols. The authors concluded that intravenous longevity therapy, including glutathione infusion, should be regarded as experimental rather than evidence-based.
- 39Revisión2026
Efficacy and Safety of Glutathione Supplementation in Patients with HIV Infection and HIV-Tuberculosis Co-Infection
Dawi J, Affa S, Au S, et al. · Nutrients · review of mechanistic studies, clinical trials and translational research on glutathione and precursor supplementation in HIV and HIV-tuberculosis co-infection
Persistent glutathione deficiency was described in HIV infection despite effective antiretroviral therapy, contributing to immune dysfunction and inflammation, and was reported as further exacerbated in HIV-tuberculosis co-infection. The authors concluded that glutathione repletion by direct supplementation or precursor strategies showed supportive but not definitive evidence.
- 40Revisión2025
Exploring the Safety and Efficacy of Glutathione Supplementation for Skin Lightening: A Narrative Review
Alzahrani TF, Alotaibi SM, Alzahrani AA, et al. · Cureus · narrative review of oral, topical and intravenous glutathione in dermatology
Oral administration was associated with significant but variable reductions in melanin with limited side effects, while intravenous glutathione was linked to serious safety concerns including anaphylaxis and hepatotoxicity, compounded by the absence of standardised dosing protocols. The authors called for caution with intravenous use pending large-scale trials.
- 41Reporte de caso2025
Intravenous Glutathione and Vitamin Supplementation Causing Stevens-Johnson Syndrome: A Case Report.
Johnson JS, et al. · J Burn Care Res · single case, 33-year-old woman after an IV vitamin infusion containing glutathione, vitamin C and vitamin D
The patient developed Stevens-Johnson syndrome/toxic epidermal necrolysis after the infusion; the authors noted prior reports implicating glutathione and a Philippine FDA warning on this association.
Hallazgo de seguridad reportado. Stevens-Johnson syndrome/toxic epidermal necrolysis followed an IV infusion containing glutathione.
- 42Reporte de caso2021
Glutathione Whitening Pills Induced Toxic Epidermal Necrolysis: An Unusual Case Confirmed by Enzyme-Linked Immunospot Assay and Liquid Chromatography-Mass Spectrometry.
Chottawornsak N, et al. · Dermatitis · single case of toxic epidermal necrolysis after oral glutathione whitening pills (no abstract)
The PubMed record has no abstract; the title reports toxic epidermal necrolysis induced by glutathione whitening pills, with the attribution supported by enzyme-linked immunospot assay and liquid chromatography-mass spectrometry. Further details are not available in the abstract.
Hallazgo de seguridad reportado. Toxic epidermal necrolysis was attributed to glutathione whitening pills.
- 43Reporte de caso2018
Seven cases of probable endotoxin poisoning related to contaminated glutathione infusions.
Johnstone T, et al. · Epidemiol Infect · case series, seven people who received compounded glutathione infusions, five of them for Lyme disease
All seven cases were assessed as probable endotoxin poisoning linked to contaminated compounded glutathione. The authors highlighted the risks of compounded sterile preparations used for unapproved indications.
Hallazgo de seguridad reportado. Seven people developed probable endotoxin poisoning after infusions of contaminated compounded glutathione.
Lo que esta evidencia no establece.
Intravenous glutathione is not an approved treatment for skin lightening, anti-ageing or general wellness in any major jurisdiction, and for those uses controlled efficacy data for infusion are essentially limited to a single placebo-controlled dermatology study; in other settings, two large intravenous trials in contrast-induced kidney injury (825 and 505 patients) and a phase 3 trial in chemotherapy neuropathy found no benefit on their main endpoints, while smaller infusion trials reported mixed results; reported harms include anaphylaxis, hepatotoxicity and cardiomyopathy in one intranasal trial participant. Oral bioavailability remains disputed and highly formulation-dependent, most trials ran 4 weeks to 6 months in fewer than 60 participants, effects on blood glutathione revert after washout, and there are no long-term safety data for repeated parenteral administration.
Preguntas comunes sobre la investigación.
- What is glutathione?
Glutathione is the tripeptide gamma-L-glutamyl-L-cysteinyl-glycine, present in most mammalian cells at millimolar concentration. Its gamma-linkage resists ordinary peptidases and its cysteine thiol group carries out its redox chemistry. This product is the reduced form, supplied lyophilised as a 1,500 mg research vial.
- What is the difference between GSH and GSSG?
GSH is the reduced form with a free thiol; GSSG is the oxidised disulfide dimer formed when two GSH molecules donate electrons. Glutathione reductase converts GSSG back to GSH using NADPH, and the ratio between the two is the standard laboratory marker of cellular redox state.
- Why do the oral and intravenous studies disagree?
Oral glutathione is substantially broken down in the gut and resynthesised intracellularly from cysteine, glutamate, and glycine, so oral dosing does not deliver the intact tripeptide to circulation the way parenteral routes do. One randomised oral trial reported increased body stores while a crossover study of oral supplementation found no change in the oxidative-stress biomarkers it measured — a discrepancy the literature attributes largely to route and bioavailability.
Disponible en nuestro catálogo
Solo para fines de investigación. No apto para consumo humano, diagnóstico, tratamiento o prevención de ninguna condición. Nada en esta página constituye consejo médico, y ningún estudio resumido aquí debe leerse como una recomendación.